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A B S T R A C T
Background
Caffeine has a variety of pharmacological effects; it is a weak bronchodilator and it also reduces respiratory muscle fatigue. It is chemically
related to the drug theophylline which is used to treat asthma. It has been suggested that caffeine may reduce asthma symptoms and
interest has been expressed in its potential role as an asthma treatment. A number of studies have explored the effects of caffeine in
asthma; this is the first review to systematically examine and summarise the evidence.
Objectives
To assess the effects of caffeine on lung function and identify whether there is a need to control for caffeine consumption prior to either
lung function or exhaled nitric oxide testing.
Search methods
We searched the Cochrane Airways Group trials register and the reference lists of articles (August 2011). We also contacted study
authors.
Selection criteria
We included randomised trials (RCTs) of oral caffeine compared to placebo or coffee compared to decaffeinated coffee in adults with
asthma.
Data collection and analysis
Two review authors independently carried out trial selection, quality assessment and data extraction.
Main results
We included seven trials involving a total of 75 people with mild to moderate asthma. The studies were all of cross-over design.
Six trials involving 55 people showed that in comparison with placebo, caffeine, even at a ’low dose’ (less than 5 mg/kg body weight),
appears to improve lung function for up to two hours after consumption. Forced expiratory volume in one second (FEV1) showed a
small improvement up to two hours after caffeine ingestion (standardised mean difference 0.72; 95% confidence interval 0.25 to 1.20),
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which translates into a 5% mean difference in FEV1. However in two studies the mean differences in FEV1 were 12% and 18% after
caffeine. Mid-expiratory flow rates also showed a small improvement with caffeine and this was sustained up to four hours.
One trial involving 20 people examined the effect of drinking coffee versus a decaffeinated variety on the exhaled nitric oxide levels in
patients with asthma and concluded that there was no significant effect on this outcome.
Authors’ conclusions
Caffeine appears to improve airways function modestly, for up to four hours, in people with asthma. People may need to avoid caffeine
for at least four hours prior to lung function testing, as caffeine ingestion could cause misinterpretation of the results. Drinking
caffeinated coffee before taking exhaled nitric oxide measurements does not appear to affect the results of the test, but more studies are
needed to confirm this.
P L A I N L A N G U A G E S U M M A R Y
The effect of caffeine in people with asthma
Caffeine is found in coffee, tea, cola drinks and cocoa. Caffeine is a drug that is very similar to theophylline. Theophylline is a
bronchodilator drug that is taken to open up the airways in the lungs and therefore relieve the symptoms of asthma, such as wheezing,
coughing and breathlessness. Scientists are interested in finding out whether caffeine has the same effect on the lungs as theophylline.
There are two major reasons why it is important to know if caffeine is a bronchodilator. The first is because it may be beneficial for
asthmatics to take caffeine in order to relieve the symptoms of asthma. The second is because consuming caffeine may affect the results
of important tests that determine how bad someone’s asthma is.
If caffeine acts as a bronchodilator and widens the airways, then a patient who has consumed caffeine before taking the test would show
a better result in a lung function test than they would have if they had not consumed any caffeine. The potential problem with this is
that if the test results are better than expected doctors may prescribe a lower dose or a weaker drug than is really necessary, which can
lead to problems with asthma management.
This review carefully examines all the available high-quality clinical trials on caffeine in asthma. This review was conducted to discover
if people should avoid consuming caffeine before taking lung function tests.
This review found that even small amounts of caffeine can improve lung function for up to four hours. Therefore caffeine can affect
the result of a lung function test (e.g. spirometry) and so caffeine should be avoided before taking a lung function test if possible, and
previous caffeine consumption should be recorded.
It is not known if taking caffeine leads to improvements in symptoms. It may be that in order to improve the symptoms of asthma,
caffeine is needed in such large amounts that the drug’s adverse effects would become a problem, so more research is needed.
Another clinical trial looked at the effect of caffeine on exhaled nitric oxide levels and found that there is no significant effect, so it
appears unlikely that patients would need to avoid caffeine before taking this type of test. However, this is the result of just a single
study so more research is needed to clarify this.
B A C K G R O U N D
Caffeine has been widely consumed throughout the world for cen-
turies. It is used for both non-medical and medical purposes. It is
ubiquitous, being found in coffee, tea, cola-flavoured soft drinks
and compounds containing cocoa. Caffeine and its derivatives
have therapeutic uses and are contained in medicines such as anal-
gesics and cold remedies.
The general pharmacological effects of caffeine have been ex-
tensively investigated and are described in several reviews (e.g.
Curatolo 1983; Stephenson 1977). Early studies reported that caf-
feine improved mental performance and increased motor activity
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(Cheney 1935) and this has been confirmed in other studies. Caf-
feine ingestion has also been shown to elevate oxygen consumption
(Grollman 1930), increase respiratory rates in disease-free patients
(Robertson 1978) and increase ventilation in patients with coro-
nary obstructive pulmonary disease (COPD) (Woodcock 1981).
Caffeine belongs to a group of chemicals called methylxanthines,
along with the bronchodilator drug theophylline. As a class, these
drugs have a history of use in respiratory disorders. The mecha-
nism of action of the methylxanthines is uncertain, but is possibly
due to their inhibition of the enzyme phosphodiesterase. Phospho-
diesterase hydrolyses cyclic adenosine monophosphate (cAMP)
which is a messenger within the cell that regulates many func-
tions including the contraction and relaxation of smooth muscle.
Methylxanthines are also competitive antagonists for adenosine
receptors. One of the effects of adenosine, a chemical regulator,
is that of bronchoconstriction. Methylxanthines are known to be
weak bronchodilators and they also interact with respiratory mus-
cles to reduce respiratory muscle fatigue. Some believe the latter to
be more important than the former in the treatment of respiratory
diseases.
Thus, interest has been expressed in the potential role of caffeine
as a treatment in respiratory disease (Pagano 1988). As early as
1859, Salter (in Becker 1984) recommended coffee as one of the
best remedies for asthma. A study of the general Italian population
in 1983 by Pagano 1988 found an inverse relationship between
the prevalence of bronchial asthma and the amount of coffee con-
sumed. From this, the authors suggested that caffeine may reduce
asthma symptoms.
Why it is important to do this review
Despite the amount of information regarding caffeine and its po-
tential effectiveness in obstructive airways diseases, no reviews have
been conducted that examine the evidence in a systematic fashion.
The results from such a review could have important implications
for research and clinical practice.
O B J E C T I V E S
1. To identify all published randomised controlled trials of
caffeine in the management of asthma.
2. To assess the methodological quality of these randomised
controlled trials.
3. To estimate the overall effect of caffeine upon lung function
and exhaled nitric oxide (FeNO).
4. To test whether there is a need to control for caffeine
consumption prior to lung function testing and testing exhaled
nitric oxide (FeNO).
5. To examine the need for further research into the effects of
caffeine in asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials (RCTs) only.
Types of participants
We included adults (older than 18 years) with previously docu-
mented asthma of any level of severity.
Types of interventions
We included the following comparisons:
1. oral caffeine versus placebo; and
2. coffee versus decaffeinated coffee.
Types of outcome measures
We did not use outcome measures to decide if a study was eligible
for inclusion in the review.
We did not include challenge test data in this review.
Primary outcomes
1. Lung function outcomes used were: forced expiratory
volume in one second (FEV1), maximum mid-expiratory flow
(FEF25-75) and specific airway conductance (Gaw/VL)
2. Exhaled nitric oxide concentration (FeNO)
Secondary outcomes
1. Forced vital capacity (FVC)
2. Maximal expiratory flow rates at 25% and 50% of vital







9. Serum caffeine levels
10. Side effects and adverse effects.
3Caffeine for asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Search methods for identification of studies
Electronic searches
We identified trials using the Cochrane Airways Group Spe-
cialised Register of trials (CAGR), which is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, CINAHL, AMED and PsycINFO, and handsearching
of respiratory journals andmeeting abstracts (see Appendix 1).We
searched all records in the Specialised Register coded as ’asthma’
using the following terms:
caffeine* or *caffeine or coffee or tea or chocolate or cola.
We did not exclude trials on the basis of language. We searched
the CAGR up to August 2011.
Searching other resources
Wereviewed reference lists of all primary studies and review articles
for additional references.
We contacted authors of identified trials and asked them to identify
other published and unpublished studies.
Data collection and analysis
Selection of studies
Two of us (AB, EB) independently reviewed the title, abstract and
key words of the references obtained from the literature search.
For the 2009 and 2011 update this was done by EJW and CC.We
excluded all studies that were not randomised trials or that clearly
did not fit the inclusion criteria. Two of us reviewed the full text
of the remaining articles. Complete agreement was achieved at all
stages.
Data extraction and management
We contacted trial authors in an effort to obtain raw and missing
data for the original review. Two of us (AB, EB) independently
extracted means and standard deviations or standard errors. We
converted standard errors to standard deviations. Two research
staff from the Division of Physiological Medicine, St. George’s
Hospital Medical School (Sally Spencer and Catherine O’Leary)
extracted data visually from graphs. There was little variation in
the data extracted by the four review authors. We used the mean
figures from the four independently extracted sets in this review.
Only data from cross-over studies were available for inclusion in
this review. Since caffeine is a short-acting agent and most studies
reported washout periods, ’carryover’ and ’period’ effects were not
considered to affect the results in an important way. They were
treated as parallel designs in the analyses for the original review,
but for the 2009 update we have used paired t-test results with
Generic Inverse Variance pooling. In addition, since no results
were reported from parallel-group studies, there was no need to
provide subgroup analyses on the basis of design.
We entered extracted data into the Cochrane Collaboration soft-
ware program (RevMan 5.1).
In one paper (Bukowskyj 1987) the mean value provided in the
table and that in the corresponding figure were inconsistent (value
for % change FEF25-75 at 0.5 hours); this was assumed to be a
misprint and therefore omitted from the meta-analysis.
Assessment of risk of bias in included studies
For this 2009 update, two of us (EW and CC) updated the risk of
bias according to four domains:
1. allocation generation and concealment;
2. blinding;
3. handling of missing data; and
4. selective reporting bias.
For each domain we judged the risk of bias as being high, low
or unclear risk of bias in line with recommendations from the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008).
Measures of treatment effect
We reported individual and pooled statistics as odds ratios (OR)
with 95% confidence intervals (95%CI).We used weightedmean
difference (MD) when identical units of measurement were re-
ported. To allow the combination of studies where different units
(e.g. actual values, change scores, % predicted values) were re-
ported for a particular pulmonary function test (e.g. FEV1 or
FEF25-75), we performed analyses using the standardised mean
difference (SMD).
Unit of analysis issues
Outcomes were measured and reported at a variety of different
time points and following different doses of caffeine. For the pur-
poses of this review and meta-analysis, we grouped data for each
outcome according to time of measurement. We divided data into
three time frames labelled as follows: ’short’ (less than or equal
to two hours); ’medium’ (greater than two hours and less than or
equal to four hours); and ’long’ (greater than four hours). In the
2009 review a comparison of all doses at two hours was included;
where no data at two hours were given we used the nearest data
point and recorded the time in Table 1.
Dealing with missing data
Since the trials were run over a few hours there were few dropouts.
Out of a total of 75 patients only six dropped out.
4Caffeine for asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data synthesis
We analysed continuous data using the inverse-variance fixed-ef-
fect method in RevMan 5.1.
Subgroup analysis and investigation of heterogeneity
For each outcome in each time frame, we performed subgroup
analyses to test for differences between ’high’ and ’low’ doses of
caffeine. Using the median value to divide the data, we defined
doses as: ’high’ (greater than 5 mg/kg (mg per kg of body weight));
or ’low’ (lower than 5 mg/kg).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
An all years literature search to 2011 returned 23 references. We
discarded 13 on the basis of the title, abstract or title and abstract.
We obtained full papers for the remaining 10 references.We iden-
tified 17 additional references by searching the bibliographies of
the retrieved studies.
Seven trials fulfilled the inclusion criteria and were included in
this review. Complete agreement was achieved between the review
authors.
Included studies
Six studies were included in the original review and an update
search conducted in August 2009 identified one additional study
which met the inclusion criteria (Taylor 2004). All studies are
outlined in the Characteristics of included studies table.
Six studies tested for the effects of caffeine on pulmonary function,
although the main aim of these studies differed. Three studies of
these six additionally tested the influence of caffeine on bronchial
provocation challenge tests, one using histamine (Colacone 1990),
one carbachol (Crivelli 1986) and one using eucapnic voluntary
hyperventilation (EVH) (Duffy 1991). We did not include chal-
lenge test data in this review. One study also tested the effect of
caffeine on exercise-induced bronchoconstriction (Kivity 1990).
One study also compared caffeine to aminophylline (Gong 1986),
but these data were not analysed as it was considered to be beyond
the scope of this review.
One study (Taylor 2004) assessed the effects of coffee on exhaled
nitric oxide (FeNO).
Participants
Therewere 55 (39male) adult participants in the six included stud-
ies testing for pulmonary function in the original review. These pa-
tients were all described as having stable,mild tomoderate asthma.
Further details of baseline lung function are found in Table 1.
There were 20 adult participants (gender not specified) in the
study testing for exhaled nitric oxide included in the 2009 update.
The severity of their asthma was not described, but there were 10
steroid-naive and 10 steroid-treated patients.
Interventions
Caffeine and matched placebos were administered orally (as a so-
lution = three studies, capsule = two studies, decaffeinated coffee
plus caffeine = one study, caffeine versus decaffeinated coffee =
one study). Two studies contributed to the ’low’ dose comparison:
Bukowskyj 1987 (5 mg/kg) and Colacone 1990 (5 mg/kg). Four
studies contributed to the ’high’ dose comparison: Crivelli 1986
(6 mg/kg), Duffy 1991 (10 mg/kg), Gong 1986 (7.2 mg/kg) and
Kivity 1990 (7 mg/kg).
One study, Taylor 2004, assessed drinking a cup of coffee (inter-
vention group) versus decaffeinated coffee (placebo group) pre-
pared using a standard quantity (15 g) of either caffeine-contain-
ing coffee or decaffeinated coffee.
Outcomes
Pulmonary function testswere the only outcomes suitable for entry
into the meta-analysis.
See Characteristics of included studies for details of secondary
outcomes of trials.
Excluded studies
From examination of the full papers of the of the potentially eligi-
ble references, we excluded two studies (Becker 1984; Henderson
1993). One potentially eligible reference was returned from the
bibliographic search and this was excluded on retrieval of the full
paper (Simmons 1983). See Characteristics of excluded studies.
Risk of bias in included studies
Complete agreement was reached by the review authors for both
assessments. See Characteristics of included studies for ’Risk of
bias’ tables for individual studies and Figure 1 for an overview.
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All the papers stated that the trials were randomised. One trial
reported computerised sequence generation which was judged to
have a low risk of bias (Gong 1986), while the remaining six trials
were unclear. Two trials reported adequate allocation concealment
(Bukowskyj 1987; Colacone 1990) while the remaining five were
unclear.
Blinding
All the studies were described as double-blind. Blinding of the
patient is important so that they put the same effort into lung
function testing regardless of intervention, however they would
presumably be able to detect if they had ingested any caffeine due
to side effects. Five studies were judged to have a low risk of bias
with respect to blinding (Bukowskyj 1987; Colacone 1990; Duffy
1991; Gong 1986; Kivity 1990). None of the papers described
blinding of the investigator administering the caffeine or placebo
to the patient or the investigator taking the outcome readings.
Incomplete outcome data
Since the trials took place over relatively short time frames there
were few dropouts and only one missing data point throughout
all the studies. All trials were judged to be of low risk of bias with
respect to dealing with incomplete data.
Other potential sources of bias
All the included studies used a cross-over design. In all cases the
cross-over rule was time. The time period between study days was
not always stated but, where details were provided, ranged from
consecutive days to within two weeks. To control for the effects of
circadian rhythms, tests took place at the same time on each day
in all studies. Few studies comment on the existence or effect of
outlying values.
Effects of interventions
Outcomes relating to lung function
The description of the analysis will follow the list of comparisons
used in this Cochrane Review and will concentrate on caffeine
versus placebo results. Subgroup analyses will highlight the ’low’
dose versus ’high’ dose and time of final assessment comparisons.
Results:
• Forced expiratory volume in one second (FEV1): ’short’
(standardised mean difference (SMD) 0.72; 95% confidence
interval (CI) 0.25 to 1.20; six studies on 78 participants),
’medium’ (mean difference (MD) 12.66; 95% CI -0.34 to 25.67;
two studies on 34 participants), ’long’ (MD 11.00; 95% CI -
6.49 to 28.49; one study on 16 participants).
• Maximum mid-expiratory flow (FEF25-75): ’short’ (MD
25.14; 95% CI 11.92 to 38.37; two studies on 34 participants),
’medium’ (MD 32.72; 95% CI 16.26 to 49.17; two studies on
34 participants), ’long’ (MD 26.00; 95% CI 5.02 to 46.98; one
study on 16 participants).
• Specific airway conductance (Gaw/VL): ’short’ (MD 30.30;
95% CI 1.08 to 59.52; one study on 18 participants).
An improvement was seen for all outcomes after ingesting caffeine
compared to placebo at all recorded time frames. This effect was
statistically significant in all cases except for FEV1 at the ’medium’
and ’long’ time frames where the confidence intervals crossed the
line of no effect.
Subgroup analysis: ’low’ dose
Two studies on 36 participants reported FEV1 outcomes at ’low’
dose. Data for the three time frame comparisons came from the
following number of studies: ’short’ = two studies, ’medium’ = one
study, ’long’ = one study. For FEF25-75 only one study on 16
participants contributed data at all time frames. There were no
data for Gaw/VL at this dose.
All lung function parameters tended to improve post caffeine in-
gestion compared to placebo. For FEV1, this effect was clear only
at the ’short’ time frame. For FEF25-75, the difference was clear
at all times.
Subgroup analysis: ’high’ dose
Four studies on 42 participants reported FEV1 outcomes at ’high’
dose. Data were available for the meta-analysis from two studies
at the ’short’ and one study at the ’medium’ time frame. No FEV1
data were reported at the ’long’ time frame. For FEF25-75, one
study on 16 participants only contributed data at the ’short’ and
’medium’ time frames. One study provided data for Gaw/VL at
the ’short’ time frame only.
Lung function was found to improve following a ’high’ dose of
caffeine compared to placebo for all measured outcomes. This
effect was clear at the ’short’ time frame only for FEV1 and FEF25-
75. A clear improvement in Gaw/VL was also seen at the ’short’
time frame.
Two other studies (Crivelli 1986; Duffy 1991) tested the effect of
’high’ dose caffeine at the ’short’ time frame on FEV1, but no data
were extracted for inclusion into the meta-analysis in the origi-
nal review. However, in correspondence, both authors reported
no significant difference in bronchodilation between caffeine and
placebo ingestion. For the 2009 update, data were extracted from
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Crivelli 1986 from the original patient data provided into FEV1
outcomes at two hours.
Subgroup analysis: FEV1 outcomes at two hours
In order to draw an overall conclusion we felt that it would be
helpful to have a comparison with as many studies side by side
as possible (2009 update). Peak FEV1 readings were recorded at
around two hours, so this was chosen as the best time point (see
Table 1). Crivelli 1986 reported a reading of FEV1 at 45 minutes
rather than two hours and these data were included in the meta-
analysis. Data were extracted from the patient data provided in
Crivelli 1986. Five studies on 88 participants gave FEV1 readings
at ’high’ doses and one study on 20 participants gave an additional
reading at ’low’ dose (Analysis 1.8). The forest plot shows im-
proved FEV1 when patients had consumed caffeine at high dose
prior to testing (SMD 0.76; 95% CI 0.32 to 1.20). There was no
heterogeneity in the result (I2 = 0) indicating a good agreement in
the outcome data between studies.
For this update we entered the paired t-test results into the review
using Generic Inverse Variance pooling for the two-hour FEV1
outcome. The confidence intervals for each trial were fairly similar
to those found previously, when the results had not been analysed
with paired t-tests. This provides reassurance that the previous
conclusions of the review are valid.
When analysed as % change in FEV1 the pooled result of three
trials on 26 participants showed a significant benefit with caffeine
at higher dose (MD 5.47%; 95% CI 1.43 to 9.52, Analysis 1.9)
(see Figure 2). There was significant heterogeneity in this result
(I2 = 61%), but this appears to come from Crivelli 1986; the
participants in this trial were asymptomatic and not on treatment
for asthma, so would have little potential to increase their FEV1
following caffeine. If the results of the two other trials (Bukowskyj
1987;Gong 1986) are combined this gives a largermean difference
with caffeine of around 15% difference in FEV1 (MD 14.54%;
95% CI 5.35 to 23.72).
Figure 2. Forest plot of comparison: 1 All caffeine doses (highest dose from each study) versus placebo,
outcome: 1.10 FEV1 outcomes at 2 hours (High dose).
Serum caffeine levels
The papers differed in their reporting of serum caffeine levels.
After a dose of caffeine (5 mg/kg), Bukowskyj 1987 reported a
peak serum level of 8.7 (SD=1.7)µg/mLone hour after ingestion.
8Caffeine for asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Colacone 1990 used the same dose and reported a mean (but not
peak) level at 1 hour 45 minutes of 5.4 (SD = 1.23) µg/mL. Duffy
1991 reported that peak serum levels of caffeine (mean 18.8; 95%
CI 12.4 to 25.2 mg/L at 45 minutes) were observed 45 to 60
minutes after ingestion of caffeine (10 mg/kg).
Taylor 2004 reported that at 60 minutes, serum caffeine levels
were higher after ingesting regular caffeine-containing coffee than
after decaffeinated coffee at 60 minutes (3.9 versus 0.4 mg/mL
respectively). Statistical tests of significance were only reported for
within-group differences.
Side effects and adverse effects
Five of the studies commented on side effects, including heart
rate and blood pressure changes although none contributed data
that could be entered in a meta-analysis. No side effects were
reported after ’low’ doses of caffeine. After ingestion of a ’high’
dose of caffeine two patients reported mild tremor (Kivity 1990),
three patients reported nervousness and gastrointestinal upset (
Gong 1986), and one patient withdrew from the study because
of nervousness and agitation (Duffy 1991), which was presumed
to be due to the caffeine. Only one study (Gong 1986) reported
significant changes in heart rate (a decrease up to 9%) and blood
pressure (an increase up to 12%).
Outcomes relating to exhaled nitric oxide
The impact of caffeine on FeNO was assessed in one study on 20
participants (Taylor 2004). This small study reported no signifi-
cant difference in exhaled nitric oxide (data reported in the text
as non-significant (P = 0.38) and presented graphically). Findings
were not significantly different in subgroups for those treated with
inhaled steroids and those not treated with steroids.
D I S C U S S I O N
The available evidence of the effect of caffeine compared toplacebo
on lung function and exhaled nitric oxide from randomised con-
trolled trials is summarised in this systematic review.
Summary of main results
For all dose strengths, caffeine compared to placebo was found to
significantly improve lung function measured in terms of FEV1,
FEF25-75 and Gaw/VL for up to two hours post ingestion. This
effect was sustained for FEF25-75 for over four hours. Improve-
ment was also seen in FEV1 up to this time, however this effect
did not reach statistical significance. No data were available for
Gaw/VL after two hours. Bronchodilation was also seen after in-
gesting caffeine even following a ’low’ dose (5 mg/kg). For FEV1,
the difference between the caffeine and placebo groups was not
significant after two hours. In contrast, for FEF25-75 the effect
was clear at all times, even over four hours. A clear increase follow-
ing a ’high’ dose of caffeine (> 5 mg/kg) compared to placebo was
seen in FEV1, FEF25-75 and Gaw/VL at up to two hours only.
Gaw/VL outcomes were not recorded beyond two hours. At two
hours, at all doses, there was an improvement in lung function
after ingesting caffeine, and when reported as % increase in FEV1
this showed an average difference of 5% change (MD5.47%; 95%
CI 1.43 to 9.52). However when the study on patients who were
asymptomatic and on no treatment (Crivelli 1986) was excluded,
the change in FEV1 was higher after caffeine (MD 14.54%; 95%
CI 5.35 to 23.72).
The size of improvements in lung function were small and at the
margins ofwhatwouldnormally be considered clinical significance
(FEV1: maximum 13.7% change from baseline (Gong 1986) or
maximum 330 mL absolute change for caffeine versus placebo
(Kivity 1990)). Only one study (Gong 1986) explicitly recorded
the patients’ perception: four of the nine participants reported
improved breathing following ingestion of a ’high’ dose of caffeine;
the same information was not provided for the placebo group.
Concerns have been raised as towhether caffeine interfereswith the
measurement of exhaled nitric oxide levels, based on a randomised
study in non-asthmatic healthy volunteers (Bruce 2002). The only
randomised study to date in a small sample of people with mild
asthma did not identify a significant difference between a cup of
coffee made with 15 g of grounds and a similar cup made with
decaffeinated coffee (Taylor 2004). Additional studies would help
to determine whether this finding is valid.
Overall completeness and applicability of
evidence
Comparison of the findings across studies was complicated by the
use of five different doses of caffeine, different outcome measures
recorded at different times, and different methods of reporting
outcomes. To permit the aggregation of data we grouped the trials
according to dose and time. Similarly, we made analyses using the
SMD where the combined trials used different units of measure-
ment for the same variable. Despite this, few data were available
to be combined in the meta-analysis.
The dose of caffeine tested varied greatly between studies, from 5
to 10 mg/kg. In an effort to make this more meaningful in dietary
terms, most authors related doses to cups of coffee. However, the
average amount of caffeine per cup is quoted as between 30 to 150
mg, although 150 mg was most commonly stated. Consequently,
the number of cups of coffee required to produce bronchodilation
is reported from one to five cups.
One method of standardising the dose ingested between studies
would be to examine the peak serum levels. The reported peak
serum levels vary greatly: from 5.4 mg/L (Colacone 1990) to 18.8
mg/L (Duffy 1991). Interestingly, the study reporting serum caf-
feine level of 18.8 mg/L after a dose of caffeine (10 mg/kg) found
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no increase in FEV1, although a later protective effect against
bronchoconstriction post broncho provocation challenge test was
found (Duffy 1991). These data were not presented in a way that
would enable extraction for entry into the meta-analysis. Peak
serum levels of caffeine tended to occur at 45 or 60 minutes
post caffeine intake. However, a clear difference between caffeine
and placebo was seen even four hours post ingestion (Bukowskyj
1987). Few studies reportedmeasurements beyond four hours post
dosing. However, serum caffeine was detected in some patients at
baseline. It is not knownwhether this would affect the potential for
bronchodilation, especially where lung function outcomes were
reported in terms of change from baseline. Even consideration of
the peak serum levels would not fully compensate for this.
The findings of any review are only applicable to the characteristics
of the participants taking part in the included studies. Although
a standardised definition was not used across the studies, partici-
pants were described as having mild or moderate asthma, therefore
results may not be generalisable to those with more severe asthma.
Most subjects were described as having stable or asymptomatic
asthma, but how this was assessed was not described. Similarly,
patients’ treatment regimens varied greatly across the trials and the
effect of this was not studied.
It could be argued that insufficient data were presented on side
effects resulting from caffeine, however the studies were designed
not to asses the long-term effects of caffeine, but instead to as-
sess the short-term impact of ingesting caffeine on lung function
and exhaled nitric oxide tests. The side effects of caffeine are sim-
ilar to those of theophylline (tachycardia, palpitation, nausea and
other gastrointestinal disturbances, headache, central nervous sys-
tem stimulation, insomnia).
The issue arising from this review is not whether caffeine should
or should not be used as a bronchodilator in preference for theo-
phylline or whether the side effects are sufficient to override this
benefit. Instead the issue is whether or not the amount of caffeine
ingested in a cup of coffee (or two) is sufficient to alter the result
of a lung function test. This may be important if coffee drinkers
show better results in lung function tests than they would achieve
if they did not drink coffee. The evidence presented here shows
that taking a ’normal’ amount of caffeine, equivalent to one to
five cups of coffee, is enough to alter the results of a lung func-
tion test. Therefore patients should be advised not to drink coffee
for four hours before taking a lung function test. Drinking coffee
before taking a FeNO test does not affect the results according
to the single-study data presented here, although further data are
necessary to clarify. The long-term impact of drinking coffee was
not studied in these trials or reviewed here.
Quality of the evidence
Interpretation of the results of this review must include consider-
ation of methodological limitations. All of the studies employed
a cross-over design. Although the method of allocation was in all
cases reported to be randomised, none of the authors assessed or-
der effects, and only two authors explicitly stated that the patients
could not discern which treatment they had received (Bukowskyj
1987; Gong 1986). Sample sizes were small and the existence or
effect of outlying values were rarely discussed. Outlying values are
important in small studies using cross-over designs, as each subject
provides a large proportion of the data.
This review was restricted to an analysis of clinically relevant data
in terms of a patient response and excluded the scientific issue of
whether caffeine affects airway response to bronchoconstricting
agents.
Potential biases in the review process
The possibility of publication bias (non-publication of negative
studies) should be considered given that only small differences in
bronchodilator effect were found between caffeine and placebo.
However, we used a comprehensive search strategy and searched
for unpublished trials in an attempt to minimise this bias.
Agreements and disagreements with other
studies or reviews
There are no other published reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Caffeine, even at ’low’ doses, has been found to improve lung
function for at least four hours after ingestion. One trial using the
most sensitive outcome measurements (FEF25-75) showed that
effects are sustained for over four hours post ingestion. It is there-
fore recommended that patients be advised to withhold caffeine
for at least four hours prior to lung function testing. Alternatively
lung function tests results should be considered in light of caffeine
ingested within four hours of the start of the test, as coffee drinkers
may present with a better lung function test result than if they had
not consumed so much caffeine. Caffeine does not appear to have
a significant effect on exhaled nitric oxide levels.
With regard to advice to patients, caffeine ingestion may improve
lung function in the short term. However, these trial data do not
indicate whether the effect reaches a threshold for clinical signifi-
cance in terms of an improvement of symptoms or quality of life.
This was not the purpose of trials examined in this review. It is not
known if tolerance to the bronchodilatory effects of caffeine devel-
ops in habitual consumers, which is a concern given that tolerance
has been found in studies of sleep and renal function (Curatolo
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1983). The amount of dietary caffeine required and the true ben-
efit of dietary caffeine intake would be difficult to calculate due to
the varying levels of caffeine within different foods and beverages.
It appears that a substantial intake of caffeinated products would
be needed to achieve a beneficial bronchodilatory effect and that
possible undesirable side effects may outweigh the benefits.
Implications for research
That caffeine has a bronchodilatory effect in asthma is clear from
existing research. Future studies could address the following.
1. Patients’ perception of the effect of caffeine on their asthma
and quality of life, as this has not been systematically studied.
2. The maximum length of time at which bronchodilation is
sustained, as this cannot be determined from existing trials.
3. Effects on patients with different levels of asthma severity,
since existing trials have only studied people with mild to
moderate asthma.
4. The response to caffeine of people with well-controlled
asthmatics on anti-inflammatory agents. Asthmatics using
inhaled steroids may be less responsive and this needs further
evaluation.
5. Differences in the bronchodilator effects of caffeine
between habitual consumers and non-consumers.
6. Whether caffeine ingestion alters management decisions in
asthma (based on lung function measurements).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bukowskyj 1987
Methods Randomised controlled trial
Cross-over design - double-blinded, rule = time (1 week)
Participants Ten patients admitted, 8 (4 male) completed the study
Mean age 64.8 (SD = 8) years
Severity of asthma:
Inclusion criteria: reversible obstructive airway disease, clinically stable, FEV1 < 75%
predicted value
Exclusion criteria: congestive heart failure, hepatic disease, ingestion of cimetidine, in-
gestion of oral contraceptives
Prescribed medication: 7 patients took oral theophylline and salbutamol; 3 patients took
inhaled beclomethasone dipropionate; 1 patient took inhaled beclomethasone dipropi-
onate and prednisolone
Control measure: refrained from caffeine, other methylxanthine-containing substances
and orally-administered beta-agonists for 12 h prior to and throughout 8 h study. Re-
frained from inhaling beta-agonists for 6 h prior to and throughout the 8 h study period
Interventions 5 mg/kg caffeine versus placebo as a solution in a juice drink
Outcomes % change FEV1, % change FVC, % change FEF25-75, % change Vmax50, % change
Vmax25, FEV1 % predicted, pulse, blood pressure
Notes Administration of corticosteroids was continued unchanged in those patients receiving
long-term therapy with these drugs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Low risk Allocated by pharmacist
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double-blinded”
Quote: “The medication code was known
only to the hospital pharmacists.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The two patients who withdrew
did so because they found the repeated
spirometric tests unacceptably tiring. There
was one patient who completed the study
except for the last four h of the placebo day
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Bukowskyj 1987 (Continued)
when she developed dyspnea.”
No data used from these patients
Colacone 1990
Methods Randomised controlled trial
Cross-over design, rule = time (variable, within 2 weeks)
Participants Ten adults (7 male) completed the study
Mean age 46 (SD = 17) years
Asthma severity: mild. Nine patients had previously documented increased airways re-
activity and one had seasonal asthma Symptom-free
Prescribedmedication: 7patients took inhaled beta-agonist, 5 patients took theophylline,
4 patients took inhaled corticosteroid and 2 required no medication
Control measures: no caffeine 48 h before study. Fasted for 8 h. Withheld antiasthmatic
medications according to standard guidelines for histamine broncho provocation testing.
Beta-agonists and anticholinergic drugs withheld for 8 to 12 h and theophylline for
12 h before testing. Slow-release theophylline and antihistamines withheld 48 h before
testing. Steroids continued as normal
Interventions 5 mg/kg caffeine versus placebo in a juice drink solution indistinguishable in taste and
smell
Histamine broncho provocation challenge
Outcomes Change in FEV1, PC20
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Low risk Allocated by pharmacist
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Caffeine and correspond-
ing placebo were prepared in solution and
coded by the hospital pharmacy.”
Quote: “Both solutions were indistinguish-
able by taste, colour and smell.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
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Crivelli 1986
Methods Randomised controlled trial
Cross-over design rule = time (2 consecutive days)
Participants Seven adults (6 male) completed the study
Age range 27 to 40 years
Asthma severity: asymptomatic
Included: patients with documented asthmatic airway obstruction
Excluded: pregnant women asthmatic patients with concomitant liver and/or cardiovas-
cular diseases, and patients treated with drugs affecting the hepatic microsomal enzyme
system (barbiturates, phenytoin, rifampicin etc.)
Prescribed medication: no bronchodilators, sodium cromoglycate or steroids for at least
2 weeks before the investigation
Control measures: withheld all caffeine and methyl xanthine-containing foods and bev-
erages at least 12 h prior to the experiment
Interventions 6 mg/kg caffeine versus placebo. Orange juice drink containing caffeine or a placebo





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk Method of allocation unknown
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as “double-blind” but caffeine or
saline given in orange juice somay not have
tasted the same
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Duffy 1991
Methods Randomised controlled trial
Cross-over design - double-blinded, rule = time (not stated)
Participants 12 adults (11 male) admitted, 11 males completed the study
Age range 18 to 42 years
Inclusion criteria: FVC and FEV1 > 80% predicted and at least 10% fall in FEV1
in response to EVH (eucapnic voluntary hyperventilation) broncho provocation. Non-
smokers
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Duffy 1991 (Continued)
Exclusion criteria: upper respiratory tract infection or influenza vaccination within 6
weeks before testing, an episode of asthma requiring hospitalisation or steroids within
the previous 6 weeks before testing, pregnancy, or other cardiovascular disease apart from
asthma
Prescribed medication: no daily asthma medication
Control measures: refrain from caffeine and methylxanthine-containing substances for
12 hours, and food and cigarettes for 4 hours before testing
Interventions 5 mg/kg, 10 mg/kg, placebo
EVH broncho provocation
Outcomes FEV1, FVC, % dFEV (the percentage fall in FEV1, after EVH)
Notes Quote: 8 of 11 subjects had detectable caffeine levels on the day placebo was given,
despite explicit instructions for avoidance of xanthine-containing products
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk Quote: “on three separate test days, each
individual received, in randomorder, either
placebo, 5 mg/kg caffeine or 10 mg/kg caf-
feine.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “After baseline pulmonary func-
tion tests, caffeine was given in a ran-
domized, crossover, double blind fashion.
Gelatin capsules were administered which
contained either 0 mg, 5 mg/kg or 10 mg/
kg caffeine.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout = 1 (female), due to side effects
of nervousness and agitation presumably
from the caffeine
Gong 1986
Methods Randomised controlled trial. Method of allocation computer program
Cross-over design - double-blinded, rule = time (at least 3 days)
Participants Nine (4 male)
Mean age = 35 (SD = 17) years
Inclusion criteria: stable asthma (ATS criteria), 12 years of mild to moderately severe
asthma, allergic in nature for 7 subjects, no other clinically evident disorders including
16Caffeine for asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gong 1986 (Continued)
hepatic disease or hypertension
Exclusion criteria: no subject was receiving immunotherapy
Prescribed medication: 7 = theophylline, 8 = sympathomimetic agents, 3 = inhaled
corticosteroids, 1 = oral corticosteroids, 1 = cromolyn sodium
Control measures: fasted for 4 hours prior to study and withheld the following prior to
each day of study: theophylline compounds (48 h); adrenergic agents, oral (12 h) and
inhaled (8 h); corticosteroids, oral (24 h) and inhaled (12 h); cromolyn sodium (24 h);
antihistamines (48 h); caffeine-containing beverages and medications (12 h)
Interventions Decaffeinated coffee (containing ~13 mg caffeine) plus a capsule containing amino-
phylline (200 mg)
Decaffeinated coffee (containing ~13 mg caffeine) plus a placebo (lactose) capsule
Decaffeinated coffee with additional 150 mg caffeine plus a placebo (lactose) capsule
Decaffeinated coffee with additional 300 mg caffeine plus a placebo (lactose) capsule
Decaffeinated coffee with additional 450 mg caffeine plus a placebo (lactose) capsule
Outcomes % change FEV1, FVC, FEF25-75, Gaw/VL (results given only for 7.2 mg/kg caffeine
versus placebo + 200mg aminophylline). Sampling of venous blood, whole body plethys-
mography, spirometry, respiratory rate, heart rate, sitting blood pressure, and symptoms
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by computer program
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Although they went to lengths to blind the
patients, there was no indication ofmethod
for blinding investigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
Kivity 1990
Methods Randomised controlled trial
Cross-over design - double-blinded, rule = time (within 2 weeks)
Participants 13 admitted, 10 adults (7 male) completed the study
Mean age = 19.5 (SD = 1.1) years
Inclusion criteria: documented reversible obstructive airway disease with a 20% im-
provement in either FVC or FEV1 after bronchodilator therapy, exercise-induced drop
in FEV1 of ≥ 15% from baseline, all patients clinically stable
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Kivity 1990 (Continued)
Exclusion criteria: any other chronic illness or receiving medication other than for
bronchial asthma
Prescribed medication: 2 = slow release theophylline, 10 = inhaled salbutamol. None of
the patients were receiving corticosteroids, cromolyn sodium or ketotifen
Interventions Opaque placebo capsule or opaque 3.5mg/kg caffeine capsule or opaque 7mg/kg caffeine
capsule taken with 100 mL water.
Exercise-induced bronchoconstriction
Outcomes FEV1, pulse, blood pressure
Notes Patients refrained from caffeine for 12 h, from theophylline containing drugs for 48 h,
and from inhaled beta-agonists 8 h prior to the study. The patient did not have caffeinated
drinks 24 h prior to the study day (conflicting information in paper). The patients did
not eat during the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Caffeine and placebo were given
through an opaque capsule together with
100 mL of water.” Stated double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “three patients who withdrew from
the study could not comply with multiple
visits to the clinic”.Nodata used from these
patients
Taylor 2004
Methods Randomised, double-blind, cross-over trial
Participants 20 adults (gender not specified) completed the study
Mean age: 37 (range 16 to 73) years
Inclusion criteria: regular coffee drinkers; FeNO > 10 PPB. 10 steroid-naive and 10
treated with ICS (mean dose 980 µg/d)
Exclusion criteria: oral prednisone, oral theophylline or inhaled long-acting beta-agonist
for 1 month prior to study
Control measures: caffeine withheld for 24 h. Inhaled bronchodilators withheld 6 h
Interventions Intervention: 15 g caffeine-containing coffee (Illy Espresso Caffe Macinato) prepared in
an espresso coffee maker as a 200 mL cup of coffee
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Taylor 2004 (Continued)
Placebo: 15 g decaffeinated coffee (Illy Espresso Decaffeinated Macinato) prepared in




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk Stated randomised, no information given
on method used
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Stated double-blind, but patient blinding
depends on regular and decaffeinated cof-
fee being indistinguishable by taste. No
mention of researcher blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts
ATS: American Thoracic Society
EVH: eucapnic voluntary hyperventilation
FEF25-75: maximum mid-expiratory flow
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
h: hour
ICS: inhaled corticosteroids
PPB: parts per billion
SD: standard deviationVmax25/Vmax50: maximal expiratory flow rates at 25% and 50% of vital capacity
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Becker 1984 Participants are children
Interventions are caffeine versus theophylline
Henderson 1993 Histamine broncho provocation challenge (FEV1 measured after challenge)
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(Continued)
Simmons 1983 Not a randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. All caffeine doses versus placebo




participants Statistical method Effect size
1 FEV1 outcomes at ’short’ time
frame
6 78 Std. Mean Difference (IV, Fixed, 95% CI) 0.72 [0.25, 1.20]
1.1 Low dose 2 36 Std. Mean Difference (IV, Fixed, 95% CI) 0.70 [0.02, 1.38]
1.2 High dose 4 42 Std. Mean Difference (IV, Fixed, 95% CI) 0.75 [0.08, 1.41]
2 FEV1 outcomes at ’medium’
time frame
2 34 Mean Difference (IV, Fixed, 95% CI) 12.66 [-0.34, 25.67]
2.1 Low dose 1 16 Mean Difference (IV, Fixed, 95% CI) 11.5 [-7.44, 30.44]
2.2 High dose 1 18 Mean Difference (IV, Fixed, 95% CI) 13.7 [-4.18, 31.58]
3 FEV1 outcomes at ’long’ time
frame
1 16 Mean Difference (IV, Fixed, 95% CI) 11.0 [-6.49, 28.49]
3.1 Low dose 1 16 Mean Difference (IV, Fixed, 95% CI) 11.0 [-6.49, 28.49]
3.2 High dose 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FEF 25-75 outcomes at ’short’
time frame
2 34 Mean Difference (IV, Fixed, 95% CI) 25.14 [11.92, 38.37]
4.1 Low dose 1 16 Mean Difference (IV, Fixed, 95% CI) 23.33 [6.18, 40.48]
4.2 High dose 1 18 Mean Difference (IV, Fixed, 95% CI) 27.8 [7.03, 48.57]
5 FEF 25-75 outcomes at
’medium’ time frame
2 34 Mean Difference (IV, Fixed, 95% CI) 32.72 [16.26, 49.17]
5.1 Low dose 1 16 Mean Difference (IV, Fixed, 95% CI) 35.5 [15.85, 55.15]
5.2 High dose 1 18 Mean Difference (IV, Fixed, 95% CI) 26.20 [-3.89, 56.29]
6 FEF 25-75 outcomes at ’long’
time frame
1 16 Mean Difference (IV, Fixed, 95% CI) 26.0 [5.02, 46.98]
6.1 Low dose 1 16 Mean Difference (IV, Fixed, 95% CI) 26.0 [5.02, 46.98]
6.2 High dose 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Gaw/VL outcomes at ’short’
time frame
1 18 Mean Difference (IV, Fixed, 95% CI) 30.30 [1.08, 59.52]
7.1 Low dose 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 High dose 1 18 Mean Difference (IV, Fixed, 95% CI) 30.30 [1.08, 59.52]
8 FEV1 outcomes at 2 hours 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Low dose 1 20 Std. Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.49, 1.29]
8.2 High dose 5 88 Std. Mean Difference (IV, Fixed, 95% CI) 0.76 [0.32, 1.20]
9 FEV1 outcomes at 2 hours
(High dose)
5 Mean Difference (Fixed, 95% CI) Subtotals only
9.1 % Change in FEV1 3 Mean Difference (Fixed, 95% CI) 5.47 [1.43, 9.52]
9.2 Post-treatment FEV1 litres 1 Mean Difference (Fixed, 95% CI) 0.38 [0.01, 0.75]
9.3 Change in FEV1 litres 1 Mean Difference (Fixed, 95% CI) 0.05 [-0.06, 0.16]
21Caffeine for asthma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 All caffeine doses versus placebo, Outcome 1 FEV1 outcomes at ’short’ time
frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 1 FEV1 outcomes at ’short’ time frame







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 14 (16.25) 8 2.25 (11) 0.80 [ -0.23, 1.83 ]
Colacone 1990 10 0.1 (0.09) 10 0.05 (0.06) 0.63 [ -0.28, 1.53 ]
Subtotal (95% CI) 18 18 0.70 [ 0.02, 1.38 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.043)
2 High dose
Crivelli 1986 1 0 (0) 1 0 (0) 0.0 [ 0.0, 0.0 ]
Duffy 1991 1 0 (0) 1 0 (0) 0.0 [ 0.0, 0.0 ]
Gong 1986 9 15.5 (10.9) 9 2.4 (14.6) 0.97 [ -0.02, 1.96 ]
Kivity 1990 10 3.55 (0.55) 10 3.22 (0.57) 0.56 [ -0.33, 1.46 ]
Subtotal (95% CI) 21 21 0.75 [ 0.08, 1.41 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
Total (95% CI) 39 39 0.72 [ 0.25, 1.20 ]
Heterogeneity: Chi2 = 0.42, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
-2 -1 0 1 2
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Analysis 1.2. Comparison 1 All caffeine doses versus placebo, Outcome 2 FEV1 outcomes at ’medium’ time
frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 2 FEV1 outcomes at ’medium’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 14.5 (21) 8 3 (17.5) 47.1 % 11.50 [ -7.44, 30.44 ]
Subtotal (95% CI) 8 8 47.1 % 11.50 [ -7.44, 30.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 High dose
Gong 1986 9 15.5 (12.6) 9 1.8 (24.3) 52.9 % 13.70 [ -4.18, 31.58 ]
Subtotal (95% CI) 9 9 52.9 % 13.70 [ -4.18, 31.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 17 17 100.0 % 12.66 [ -0.34, 25.67 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
-20 -10 0 10 20
Control better Caffeine better
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Analysis 1.3. Comparison 1 All caffeine doses versus placebo, Outcome 3 FEV1 outcomes at ’long’ time
frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 3 FEV1 outcomes at ’long’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 5.5 (21) 8 -5.5 (14) 100.0 % 11.00 [ -6.49, 28.49 ]
Subtotal (95% CI) 8 8 100.0 % 11.00 [ -6.49, 28.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 High dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8 8 100.0 % 11.00 [ -6.49, 28.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Control better Caffeine better
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Analysis 1.4. Comparison 1 All caffeine doses versus placebo, Outcome 4 FEF 25-75 outcomes at ’short’
time frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 4 FEF 25-75 outcomes at ’short’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 17 (11.33) 8 -6.33 (22) 59.5 % 23.33 [ 6.18, 40.48 ]
Subtotal (95% CI) 8 8 59.5 % 23.33 [ 6.18, 40.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
2 High dose
Gong 1986 9 31.8 (23.6) 9 4 (21.3) 40.5 % 27.80 [ 7.03, 48.57 ]
Subtotal (95% CI) 9 9 40.5 % 27.80 [ 7.03, 48.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
Total (95% CI) 17 17 100.0 % 25.14 [ 11.92, 38.37 ]
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 3.73 (P = 0.00019)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
-50 -25 0 25 50
Control better Caffeine better
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Analysis 1.5. Comparison 1 All caffeine doses versus placebo, Outcome 5 FEF 25-75 outcomes at ’medium’
time frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 5 FEF 25-75 outcomes at ’medium’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 25 (21.5) 8 -10.5 (18.5) 70.1 % 35.50 [ 15.85, 55.15 ]
Subtotal (95% CI) 8 8 70.1 % 35.50 [ 15.85, 55.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00040)
2 High dose
Gong 1986 9 33.1 (29.1) 9 6.9 (35.7) 29.9 % 26.20 [ -3.89, 56.29 ]
Subtotal (95% CI) 9 9 29.9 % 26.20 [ -3.89, 56.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
Total (95% CI) 17 17 100.0 % 32.72 [ 16.26, 49.17 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
-50 -25 0 25 50
Control better Caffeine better
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Analysis 1.6. Comparison 1 All caffeine doses versus placebo, Outcome 6 FEF 25-75 outcomes at ’long’
time frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 6 FEF 25-75 outcomes at ’long’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Bukowskyj 1987 8 9.5 (15.5) 8 -16.5 (26) 100.0 % 26.00 [ 5.02, 46.98 ]
Subtotal (95% CI) 8 8 100.0 % 26.00 [ 5.02, 46.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
2 High dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 8 8 100.0 % 26.00 [ 5.02, 46.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Control better Caffeine better
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Analysis 1.7. Comparison 1 All caffeine doses versus placebo, Outcome 7 Gaw/VL outcomes at ’short’ time
frame.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 7 Gaw/VL outcomes at ’short’ time frame





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 High dose
Gong 1986 9 37.8 (33.8) 9 7.5 (29.3) 100.0 % 30.30 [ 1.08, 59.52 ]
Subtotal (95% CI) 9 9 100.0 % 30.30 [ 1.08, 59.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
Total (95% CI) 9 9 100.0 % 30.30 [ 1.08, 59.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
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Analysis 1.8. Comparison 1 All caffeine doses versus placebo, Outcome 8 FEV1 outcomes at 2 hours.
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 8 FEV1 outcomes at 2 hours







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low dose
Kivity 1990 10 3.48 (0.63) 10 3.23 (0.57) 100.0 % 0.40 [ -0.49, 1.29 ]
Subtotal (95% CI) 10 10 100.0 % 0.40 [ -0.49, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 High dose
Bukowskyj 1987 8 14 (19) 8 2 (14) 18.5 % 0.68 [ -0.34, 1.70 ]
Colacone 1990 10 0.1 (0.09) 10 0.05 (0.06) 23.5 % 0.63 [ -0.28, 1.53 ]
Crivelli 1986 7 1.71 (4.5) 7 -1.57 (3.21) 15.8 % 0.79 [ -0.32, 1.89 ]
Gong 1986 9 22.5 (13.5) 9 4 (18) 18.8 % 1.11 [ 0.10, 2.12 ]
Kivity 1990 10 3.61 (0.54) 10 3.23 (0.57) 23.4 % 0.66 [ -0.25, 1.56 ]
Subtotal (95% CI) 44 44 100.0 % 0.76 [ 0.32, 1.20 ]
Heterogeneity: Chi2 = 0.62, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00069)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.48), I2 =0.0%
-2 -1 0 1 2
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Analysis 1.9. Comparison 1 All caffeine doses versus placebo, Outcome 9 FEV1 outcomes at 2 hours (High
dose).
Review: Caffeine for asthma
Comparison: 1 All caffeine doses versus placebo
Outcome: 9 FEV1 outcomes at 2 hours (High dose)





IV,Fixed,95% CI IV,Fixed,95% CI
1 % Change in FEV1
Bukowskyj 1987 12 (6) 11.8 % 12.00 [ 0.24, 23.76 ]
Crivelli 1986 3.29 (2.3) 80.6 % 3.29 [ -1.22, 7.80 ]
Gong 1986 18.5 (7.5) 7.6 % 18.50 [ 3.80, 33.20 ]
Subtotal (95% CI) 100.0 % 5.47 [ 1.43, 9.52 ]
Heterogeneity: Chi2 = 5.10, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 2.65 (P = 0.0080)
2 Post-treatment FEV1 litres
Kivity 1990 0.38 (0.19) 100.0 % 0.38 [ 0.01, 0.75 ]
Subtotal (95% CI) 100.0 % 0.38 [ 0.01, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
3 Change in FEV1 litres
Colacone 1990 0.05 (0.057) 100.0 % 0.05 [ -0.06, 0.16 ]
Subtotal (95% CI) 100.0 % 0.05 [ -0.06, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of studies used in meta-analysis




Bukowskyj 1987 5 mg/kg Aqueous solution 48 2 h
Colacone 1990 5 mg/kg Aqueous solution 84 2h
Crivelli 1986 6 mg/kg Aqueous solution -- 45 min
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Table 1. Characteristics of studies used in meta-analysis (Continued)
Duffy 1991 5 mg/kg (’low’)
10 mg/kg (’high’)
Capsules 92.9 90 min
Gong 1986 7.2 mg/kg Decaffeinated coffee
plus caffeine
56 2 h
Kivity 1990 3.5 mg/kg (’low’)
7 mg/kg (’high’)
Capsules 78.8 2 h
Taylor 2004 15 g coffee Coffee of decaffeinated
coffee
94 --
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly




Handsearches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
F E E D B A C K
Historical use of caffeine
Summary
Reading the “Background” in the Abstract, it seems that the interest by caffeine as a bronchodilator is new. As a matter of fact, caffeine
is used for asthma since, at least, the last decades of 1800. We can find reference to this drug in Marcel Proust’s “A l’Ombre de Jeunes
Filles en Fleur”. This author, an asthmatic, refers that when he was very young (he was born in 1871) he used caffeine “that was
prescribed for help me breathing”.
Reply
Thank you for this comment.
Contributors
Roni Marques, chest physician.
WH A T ’ S N E W
Last assessed as up-to-date: 10 August 2011.
Date Event Description
11 August 2011 New search has been performed New literature search run. No new eligible studies identified. Minor copy edits
made
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H I S T O R Y
Protocol first published: Issue 3, 1996
Review first published: Issue 2, 1998
Date Event Description
29 September 2009 New citation required but conclusions have not
changed
New authorship of the review.
27 August 2009 New search has been performed New search conducted, added new included study
(Taylor 2004), amendments made to Plain Language
Summary, reformatted Results and Discussion and
added ’Risk of bias’ and ’Summary of findings’ table.
Conclusions unchanged
21 July 2008 Amended Converted to new review format.
7 January 2005 New search has been performed New studies found and included or excluded: 8 Jan-
uary 2005
8 January 2003 New search has been performed New studies sought but none found: 8 January 2003
18 June 2001 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Anna Bara and Elizabeth Barley extracted the data, did the meta-analyses and drafted the original review.
Emma Welsh updated the review, reformatted and redrafted it, added a new included study (Taylor 2004) and added ’Risk of bias’
tables. Chris Cates extracted data for the ’Risk of bias’ table, carried out the Generic Inverse Variance analyses and edited the review
update.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
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Internal sources
• NHS Research and Development, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The 2009 update included regular caffeine-containing coffee versus decaffeinated coffee as a comparison type. The 2009 review also
compared lung function at all doses at two hours.
Serum caffeine levels was included as an outcome.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Respiratory Function Tests; Asthma [diagnosis; ∗drug therapy]; Bronchi [drug effects]; Bronchodilator Agents [∗pharmacology];
Caffeine [∗pharmacology]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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